A Swiss company, Comphya SA, has raised $3.0 million in funding to develop an implantable device for treating neurogenic ED.
Roughly 5-8% of erectile dysfunction cases may be neurogenic. Underlying causes include diabetes, Parkinson’s disease, multiple sclerosis (MS), spinal injuries, prostate removal surgery, and radiation treatments. When nerves are damaged, they cannot carry the impulses that trigger an erection (see our article, “How Do Erections Work?“).
Comphya hopes to develop an implantable device, based on the a study conducted in 20181.
In the study, an electrical array was place on the pelvic plexus. In the 24 test subjects, electrical stimulation produced an immediate penile response. The degree of response varied among the subjects. As expected, patients with lower International Index of Erectile Function-5 scores presented a reduced response.
Based on these results, researchers hope to develop an implantable electrical stimulator, which could be activated using an external remote control.
Comphya SA will use the funding round to complete product development and perform the pilot clinical trial. Results of the trial are expected by the end of 2020.
- Skoufias, Spyridon; Sturny, Mikaël; Fraga-Silva, Rodrigo; Papaioannou, Theodore G; Stergiopoulos, Nikolaos; Adamakis, Ioannis; Constantinides, Constantinos A. “Novel Concept Enabling an Old Idea: A Flexible Electrode Array to Treat Neurogenic Erectile Dysfunction.” The Journal of Sexual Medicine. November 2018; Volume 15, Issue 11, Pages 1558–1569.